Modified Factor VII
AssigneesNovo Nordisk A/S, ZymoGenetics, Inc.
InventorsKathleen L Berkner, Lars Christian Petersen, Charles E. Hart
Life of this patent
Estimating the term…
Abstract
The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modification renders Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
Claims5
Human Factor VII having at least one modification in its catalytic center which substantially inhibits the ability of Factor VIIa to activate plasma Factors X or IX, and wherein said modified Factor VII inhibits coagulation of human plasma, in a pharmaceutically acceptable composition.
Dependencies are inferred from the claim text.